Supernus Pharmaceuticals Inc [SUPN] stock prices are up 0.52% to $29.10 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SUPN shares have gain 2.14% over the last week, with a monthly amount glided 11.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On April 13, 2021, upgrade upgraded it’s rating to Buy and revised its price target to $40 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $31 on June 16, 2020. Berenberg downgraded its rating to Hold for this stock on November 08, 2019. In a note dated November 07, 2019, Stifel downgraded an Hold rating on this stock and revised its target price from $55 to $23.
The stock price of Supernus Pharmaceuticals Inc [SUPN] has been fluctuating between $21.99 and $35.44 over the past year. Currently, Wall Street analysts expect the stock to reach $39.67 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $29.10 at the most recent close of the market. An investor can expect a potential return of 36.32% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
The Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 597.40M for trailing twelve months, representing a drop of -6.58%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.02 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.62 points at the first support level, and at 28.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.41, and for the 2nd resistance point, it is at 29.71.
Ratios To Look Out For
It’s worth pointing out that Supernus Pharmaceuticals Inc [NASDAQ:SUPN]’s Current Ratio is 1.73. In addition, the Quick Ratio stands at 1.49 and the Cash Ratio stands at 0.2. Considering the valuation of this stock, the price to sales ratio is 2.68, the price to book ratio is 1.72.
Transactions by insiders
Recent insider trading involved Bhatt Padmanabh P., Sr. VP of IP, CSO, that happened on Mar 21 ’24 when 14491.0 shares were sold. Sr. VP of IP, CSO, Bhatt Padmanabh P. completed a deal on Mar 20 ’24 to sell 400.0 shares. Meanwhile, Sr. VP of IP, CSO Bhatt Padmanabh P. sold 12364.0 shares on Mar 19 ’24.
